Pulmonary Artery Pseudoaneurysm; Endovascular treatment of an Ominous Finding

Abstract

Abstract The technique and outcomes of pulmonary artery pseudoaneurysm embolization was retrospectively evaluated in 13 patients undergoing pulmonary PSA embolization between January 2014 and September 2023. The etiology of the PSA was iatrogenic (4/13), tumor (3/13), chronic lung (2/13), idiopathic (2/13) and mycotic (2/13). Clinical presentation was massive hemorrhage (6/13), incidental (4/13), and non-massive hemoptysis (3/13). The average PSA size was 13.5mm. Coil embolization of the PSA sac was performed in all but two extenuating cases (11/13). Follow-up of 12 patients over an average 5.3-months showed persistent occlusion in all cases. There were no major adverse events attributed to the embolization. 5/10 patients with procedures performed at least one year before this study were noted to be deceased after an average 7-month time. Pulmonary artery PSAs of various etiologies may be safely and effectively treated by embolizing the PSA sac.